LifeSci Capital analyst Rami Katkhuda downgraded Akero Therapeutics (AKRO) to Market Perform from Outperform with a $58 price target after the company entered into an agreement to be acquired by Novo Nordisk (NVO) for $54 per share in cash and a non-transferable contingent value right for up to $6 per share upon full U.S. regulatory approval of efruxifermin.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Cautious Hold Rating on Akero Therapeutics Amid Acquisition Interest and Uncertainties in Efruxifermin’s Clinical Trajectory
- Akero Therapeutics downgraded to Hold from Buy at Jefferies
- Akero Therapeutics downgraded to Hold from Buy at Canaccord
- Akero Therapeutics rises 16.5%
- Video: Delta soars after earnings, lifts airline peers